Amgen drug patent challenge slices $2B off Alexion's market cap By: Boston Business Journal via Business Journals August 30, 2019 at 11:33 AM EDT Alexion's finances rely heavily on its rare disease drug Soliris. The drug is the source of 80 percent of Alexion's annual revenue. Read More >>
